Here are the 10-Q quarterly reports from Polaryx Therapeutics, Inc. (PLYX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PLYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLYX filings page.
Polaryx Therapeutics, Inc. is a clinical-stage biotech focused on therapies for rare pediatric lysosomal storage disorders and reported continued operating losses for the quarter ended June 30, 2026. Net loss was $1.4 million for the quarter and $3.9 million for the first six months, compared with $1.0 million and $6.1 million in the prior-year periods.
Cash and cash equivalents increased to $11.5 million from $5.1 million at year-end 2025, driven by a $10.0 million May 2026 equity financing that issued 2,502,696 shares. Total assets were $11.8 million, with minimal liabilities of $0.9 million and stockholders’ equity of $10.9 million.
The company plans a Phase 2 proof-of-concept basket trial, SOTERIA, for PLX‑200 across CLN2, CLN3, Krabbe disease and Sandhoff disease, with initiation expected in the second half of 2026 and expanded enrollment to 24 participants. Management projects existing cash will fund operations through the first quarter of 2027, but recurring losses and dependence on external financing raise substantial doubt about its ability to continue as a going concern.
Polaryx Therapeutics, Inc. reported a net loss of approximately $2.5 million for the quarter ended March 31, 2026, narrower than the $5.1 million loss a year earlier. Operating expenses fell sharply as research and development declined to $679 thousand, mainly because a one-time, stock-based gene therapy license charge in 2025 did not recur.
General and administrative costs rose to $1.3 million, reflecting new public-company expenses and higher stock-based compensation to an advisor. Cash and cash equivalents were $3.1 million, with $2.1 million used in operating activities in the quarter and working capital of about $2.5 million as of March 31, 2026.
Polaryx remains a clinical-stage company with no product revenue and an accumulated deficit of roughly $102.2 million. Management discloses substantial doubt about its ability to continue as a going concern and expects existing cash to fund operations only through the third quarter of 2026, while it advances its PLX‑200 lysosomal storage disorder program toward a planned Phase 2 basket trial.